Zacks Investment Research downgraded shares of CYTOSORBENTS CP (CTSO) from OUTPERFORM to NEUTRAL on January 07, 2015, with a target price of $10.60.
CytoSorbents Corporation is a therapeutic medical device company. It develops adsorbent polymer technology for applications in the medical field, primarily to provide blood purification for the treatment of acute and chronic health complications associated with blood toxicity. The Company's product include CytoSorb, which filters cytokines and treat potentially fatal cytokine storm and BetaSorb, which remove beta2-microglobulin from the blood of patients suffering from chronic kidney failure. CytoSorbents Corporation is headquartered in Monmouth Junction, New Jersey.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on CYTOSORBENTS CP (CTSO),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment